Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma

Jonathan D. Licht, Rosemary Mazanet, Patrick J. Loehrer, René Gonin, Karen H. Antman

Research output: Contribution to journalArticle

12 Scopus citations


Intravenous-bolus etoposide has modest activity in sarcomas when given daily for 3-5 days. Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. A phase I trial of oral etoposide resulted in partial responses in two patients with soft-tissue sarcomas. To estimate more accurately the response rate for daily oral etoposide in sarcomas, we treated 25 patients with 50 mg/m2 per day by mouth for 21 days every 4 weeks. Treatment-related toxicity included≥grade 2 neutropenia in 6 of the 25 patients and thrombocytopenia in 3. One brief partial response was observed (4%; 95% confidence interval for true response rate, 0-11%). Disease stabilized in five patients for periods ranging from 3 to 18 months. At this dose and on this schedule, daily oral etoposide appears to have little activity against soft-tissue sarcomas.

Original languageEnglish (US)
Pages (from-to)79-80
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Issue number1
StatePublished - Jan 1 1994
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma'. Together they form a unique fingerprint.

  • Cite this